Clinical trial
Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1
NCT00106158 · Ludwig Institute for Cancer Research, Other · Completed
Key facts
| NCT number | NCT00106158 |
|---|---|
| Title | Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1 |
| Official title | Immunization of Patients With Tumors Expressing NY-ESO-1 or LAGE Antigen With Complex of NY-ESO-1 Protein and Cholesterol-bearing Hydrophobized Pullulan (CHP) |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Biological |
| Interventions | protein vaccination |
| Enrollment | 9 |
| Start date | Jun 1, 2004 |
| Completion | Dec 1, 2006 |
| First posted | Mar 22, 2005 |
| Last update posted | Nov 5, 2010 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: